HRP20220734T1 - Koagonisti glukagona i glp-1 za liječenje pretilosti - Google Patents
Koagonisti glukagona i glp-1 za liječenje pretilosti Download PDFInfo
- Publication number
- HRP20220734T1 HRP20220734T1 HRP20220734TT HRP20220734T HRP20220734T1 HR P20220734 T1 HRP20220734 T1 HR P20220734T1 HR P20220734T T HRP20220734T T HR P20220734TT HR P20220734 T HRP20220734 T HR P20220734T HR P20220734 T1 HRP20220734 T1 HR P20220734T1
- Authority
- HR
- Croatia
- Prior art keywords
- less
- isolated peptide
- receptor
- glp
- use according
- Prior art date
Links
- 102000051325 Glucagon Human genes 0.000 title claims 4
- 239000000556 agonist Substances 0.000 title claims 4
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 title claims 4
- 229960004666 glucagon Drugs 0.000 title claims 4
- 108060003199 Glucagon Proteins 0.000 title claims 3
- 208000008589 Obesity Diseases 0.000 title claims 2
- 235000020824 obesity Nutrition 0.000 title claims 2
- 101100337060 Caenorhabditis elegans glp-1 gene Proteins 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 24
- 108010086246 Glucagon-Like Peptide-1 Receptor Proteins 0.000 claims 7
- 102100032882 Glucagon-like peptide 1 receptor Human genes 0.000 claims 7
- 108010063919 Glucagon Receptors Proteins 0.000 claims 5
- 102100040890 Glucagon receptor Human genes 0.000 claims 4
- 102000008100 Human Serum Albumin Human genes 0.000 claims 3
- 108091006905 Human Serum Albumin Proteins 0.000 claims 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 claims 2
- 101710198884 GATA-type zinc finger protein 1 Proteins 0.000 claims 2
- DTHNMHAUYICORS-KTKZVXAJSA-N Glucagon-like peptide 1 Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(N)=O)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1N=CNC=1)[C@@H](C)O)[C@@H](C)O)C(C)C)C1=CC=CC=C1 DTHNMHAUYICORS-KTKZVXAJSA-N 0.000 claims 2
- 101001015516 Homo sapiens Glucagon-like peptide 1 receptor Proteins 0.000 claims 2
- 239000002202 Polyethylene glycol Substances 0.000 claims 2
- 102100040918 Pro-glucagon Human genes 0.000 claims 2
- 239000003446 ligand Substances 0.000 claims 2
- 125000003588 lysine group Chemical group [H]N([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 claims 2
- 125000001312 palmitoyl group Chemical group O=C([*])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 2
- 229920001223 polyethylene glycol Polymers 0.000 claims 2
- 102000009027 Albumins Human genes 0.000 claims 1
- 108010088751 Albumins Proteins 0.000 claims 1
- 102000004127 Cytokines Human genes 0.000 claims 1
- 108090000695 Cytokines Proteins 0.000 claims 1
- 102000004190 Enzymes Human genes 0.000 claims 1
- 108090000790 Enzymes Proteins 0.000 claims 1
- 101001040075 Homo sapiens Glucagon receptor Proteins 0.000 claims 1
- 102100026120 IgG receptor FcRn large subunit p51 Human genes 0.000 claims 1
- 101710177940 IgG receptor FcRn large subunit p51 Proteins 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- 241001529936 Murinae Species 0.000 claims 1
- 239000002253 acid Substances 0.000 claims 1
- 150000001413 amino acids Chemical group 0.000 claims 1
- 229960002685 biotin Drugs 0.000 claims 1
- 235000020958 biotin Nutrition 0.000 claims 1
- 239000011616 biotin Substances 0.000 claims 1
- 238000013262 cAMP assay Methods 0.000 claims 1
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 1
- 229930195712 glutamate Natural products 0.000 claims 1
- 229920000592 inorganic polymer Polymers 0.000 claims 1
- 229920000620 organic polymer Polymers 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 229920001184 polypeptide Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 108020001580 protein domains Proteins 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 102000005962 receptors Human genes 0.000 claims 1
- 108020003175 receptors Proteins 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Endocrinology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Child & Adolescent Psychology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261735823P | 2012-12-11 | 2012-12-11 | |
| EP18182274.3A EP3495380B1 (en) | 2012-12-11 | 2013-12-10 | Glucagon and glp-1 co-agonists for the treatment of obesity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20220734T1 true HRP20220734T1 (hr) | 2022-09-02 |
Family
ID=50588751
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20220734TT HRP20220734T1 (hr) | 2012-12-11 | 2013-12-10 | Koagonisti glukagona i glp-1 za liječenje pretilosti |
| HRP20181678TT HRP20181678T1 (hr) | 2012-12-11 | 2013-12-10 | Glukagon/glp-1 agonisti za liječenje pretilosti |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20181678TT HRP20181678T1 (hr) | 2012-12-11 | 2013-12-10 | Glukagon/glp-1 agonisti za liječenje pretilosti |
Country Status (26)
| Country | Link |
|---|---|
| US (4) | US9765130B2 (https=) |
| EP (2) | EP3495380B1 (https=) |
| JP (1) | JP6490011B2 (https=) |
| KR (1) | KR102080366B1 (https=) |
| CN (2) | CN104822699B (https=) |
| AR (1) | AR093903A1 (https=) |
| AU (3) | AU2013356934C1 (https=) |
| BR (1) | BR112015012238B1 (https=) |
| CA (1) | CA2893445C (https=) |
| CY (2) | CY1121114T1 (https=) |
| DK (2) | DK3495380T3 (https=) |
| ES (2) | ES2926713T3 (https=) |
| HR (2) | HRP20220734T1 (https=) |
| HU (1) | HUE039952T2 (https=) |
| LT (2) | LT2931745T (https=) |
| MX (2) | MX365458B (https=) |
| PL (2) | PL3495380T3 (https=) |
| PT (2) | PT2931745T (https=) |
| RS (2) | RS63305B1 (https=) |
| RU (2) | RU2671088C2 (https=) |
| SG (2) | SG10201801159WA (https=) |
| SI (2) | SI3495380T1 (https=) |
| SM (2) | SMT201800611T1 (https=) |
| TR (1) | TR201815172T4 (https=) |
| TW (2) | TWI617574B (https=) |
| WO (1) | WO2014091316A2 (https=) |
Families Citing this family (49)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UA116217C2 (uk) | 2012-10-09 | 2018-02-26 | Санофі | Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону |
| TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
| AU2013366692B2 (en) | 2012-12-21 | 2017-11-23 | Sanofi | Dual GLP1/GIP or trigonal GLP1/GIP/Glucagon agonists |
| CA2902352A1 (en) * | 2013-03-14 | 2014-09-18 | Medimmune Limited | Pegylated glucagon and glp-1 co-agonists for the treatment of obesity |
| EP3080152A1 (en) | 2013-12-13 | 2016-10-19 | Sanofi | Non-acylated exendin-4 peptide analogues |
| WO2015086728A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Exendin-4 peptide analogues as dual glp-1/gip receptor agonists |
| WO2015086733A1 (en) | 2013-12-13 | 2015-06-18 | Sanofi | Dual glp-1/glucagon receptor agonists |
| EP3080154B1 (en) | 2013-12-13 | 2018-02-07 | Sanofi | Dual glp-1/gip receptor agonists |
| TW201625668A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物 |
| TW201625669A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑 |
| TW201625670A (zh) | 2014-04-07 | 2016-07-16 | 賽諾菲公司 | 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑 |
| US9932381B2 (en) | 2014-06-18 | 2018-04-03 | Sanofi | Exendin-4 derivatives as selective glucagon receptor agonists |
| CN104926934B (zh) * | 2014-09-23 | 2016-11-09 | 蒋先兴 | 胃泌酸调节素类似物 |
| AR105319A1 (es) | 2015-06-05 | 2017-09-27 | Sanofi Sa | Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico |
| WO2016198628A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Non-acylated exendin-4 derivatives as dual glp-1/glucagon receptor agonists |
| WO2016198624A1 (en) | 2015-06-12 | 2016-12-15 | Sanofi | Exendin-4 derivatives as trigonal glp-1/glucagon/gip receptor agonists |
| TW201706291A (zh) | 2015-07-10 | 2017-02-16 | 賽諾菲公司 | 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物 |
| TWI622596B (zh) * | 2015-10-26 | 2018-05-01 | 美國禮來大藥廠 | 升糖素受體促效劑 |
| CN113456820B (zh) * | 2015-12-29 | 2023-09-08 | 派格生物医药(苏州)股份有限公司 | 包含glp-1受体激动剂和胰高血糖素受体激动剂的组合物及其用途 |
| ES2983409T3 (es) * | 2016-03-10 | 2024-10-23 | Medimmune Ltd | Agonista de Glp-1/glucagón para su uso en el tratamiento de la esteatohepatitis no alcohólica |
| US20190388510A1 (en) * | 2016-06-02 | 2019-12-26 | Indiana University Research And Technology Corporation | Glucagon-t3 conjugates |
| CN107281471A (zh) * | 2017-06-26 | 2017-10-24 | 中国药科大学 | 一种改构的胰高血糖素样肽－1及其修饰物的应用 |
| US11419918B2 (en) * | 2017-11-06 | 2022-08-23 | Shenzhen Turier Biotech Co., Ltd. | Treatment of biliary cirrhosis based on oxyntomodulin analogue GLP-1R/GCGR dual-target agonist peptide |
| TWI770085B (zh) * | 2017-11-21 | 2022-07-11 | 日商武田藥品工業股份有限公司 | 胜肽化合物 |
| MX2020010505A (es) | 2018-04-05 | 2021-01-15 | Sun Pharmaceutical Ind Ltd | Analogos novedosos de glp-1. |
| EP3882263A4 (en) * | 2018-11-12 | 2022-08-31 | Tianjin Institute Of Pharmaceutical Research Co., Ltd. | GLUCAGON DERIVED PEPTIDE AND USE THEREOF |
| CA3139613A1 (en) | 2019-05-21 | 2020-11-26 | Medimmune Limited | Cyclodextrin based injectable coformulations of sglt2 inhibitors and incretin peptides |
| EA202290107A1 (ru) | 2019-07-01 | 2022-03-29 | Медиммун Лимитед | Фармацевтические композиции на основе пептидов, являющихся коагонистами глюкагона и glp-1 |
| CN112898406B (zh) * | 2019-10-12 | 2023-11-10 | 深圳纳福生物医药有限公司 | 不同构型的glp-1类似肽修饰二聚体及其制备方法在治疗ii型糖尿病中的应用 |
| JP2023505126A (ja) * | 2019-12-03 | 2023-02-08 | メディミューン，エルエルシー | 肥満症の処置のためのグルカゴン及びｇｌｐ－１のコアゴニストを使用する組合せ治療 |
| TW202140061A (zh) | 2020-01-10 | 2021-11-01 | 英商梅迪繆思有限公司 | 用於治療２型糖尿病中的慢性腎病和糖尿病性腎病的升糖素及ｇｌｐ－１協同促效劑 |
| CN113493503B (zh) * | 2020-04-08 | 2022-08-05 | 浙江道尔生物科技有限公司 | 一种肠促胰岛素类似物及其制备方法和用途 |
| KR20230005289A (ko) | 2020-04-24 | 2023-01-09 | 베링거 인겔하임 인터내셔날 게엠베하 | 지방 간 질환 및 지방간염의 치료에서 장시간-작용성 glp-1/글루카곤 수용체 작용제로서 글루카곤 유사체 |
| TW202313974A (zh) | 2021-06-08 | 2023-04-01 | 瑞典商阿斯特捷利康公司 | 用於治療肝病之組合療法 |
| KR20240043778A (ko) | 2021-07-30 | 2024-04-03 | 베링거 인겔하임 인터내셔날 게엠베하 | 장시간-작용하는 glp1/글루카곤 수용체 작용제를 위한 용량 용법 |
| TW202346323A (zh) | 2022-02-07 | 2023-12-01 | 英商梅迪繆思有限公司 | 具有改善的生物穩定性的ｇｌｐ—１及升糖素雙重激動肽 |
| US20240148833A1 (en) * | 2022-11-03 | 2024-05-09 | EFIL BioScience Inc. | Composition comprising glp-1 receptor agonist and acat inhibitor |
| WO2024123812A1 (en) | 2022-12-05 | 2024-06-13 | Shattuck Labs, Inc. | Fusion proteins for the treatment of cardiometabolic diseases |
| WO2024165571A2 (en) | 2023-02-06 | 2024-08-15 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| CN115975057B (zh) * | 2023-03-16 | 2023-05-16 | 杭州信海医药科技有限公司 | 一种可妥度肽的固相合成方法 |
| KR20260022948A (ko) | 2023-06-09 | 2026-02-20 | 썬 파마슈티컬 인더스트리스 리미티드 | Glp-1/gip 이중 수용체 작용제, glp-1/gcg 이중 수용체 작용제, 및 glp-1/gip/gcg 삼중 수용체 작용제 |
| WO2025024788A1 (en) * | 2023-07-27 | 2025-01-30 | Biomedit, Llc | Stabilized glp-1 peptides and dual agonist peptides against glp-1r and gipr and methods of use thereof |
| WO2025125576A2 (en) | 2023-12-15 | 2025-06-19 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| EP4686757A1 (en) | 2024-07-31 | 2026-02-04 | e-therapeutics PLC | Inhibitors of expression and/or function |
| WO2025133348A1 (en) | 2023-12-22 | 2025-06-26 | E-Therapeutics Plc | Inhibitors of expression and/or function |
| WO2025196502A1 (en) | 2024-03-20 | 2025-09-25 | North Carolina Agricultural & Technical State University | Choline kinase inhibitors as a therapeutic treatment for obesity |
| WO2025242620A1 (en) | 2024-05-20 | 2025-11-27 | Medimmune Limited | Polypeptide combinations and uses thereof |
| CN118787658B (zh) * | 2024-06-14 | 2025-01-21 | 中国农业大学 | 一种胰高血糖素样肽-1受体特异性核酸适配体在代谢疾病干预中的应用 |
| WO2026058194A1 (en) | 2024-09-12 | 2026-03-19 | Medimmune Limited | Polypeptide dosage regimens |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US30326A (en) * | 1860-10-09 | Steam-g-eneratob | ||
| DE3572982D1 (en) | 1984-03-06 | 1989-10-19 | Takeda Chemical Industries Ltd | Chemically modified lymphokine and production thereof |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| JP2006501820A (ja) * | 2002-09-06 | 2006-01-19 | バイエル・フアーマシユーチカルズ・コーポレーシヨン | 修飾ｇｌｐ−１受容体アゴニストおよびそれらの薬理学的使用法 |
| CN1938334A (zh) * | 2004-01-30 | 2007-03-28 | 瓦拉塔药品公司 | Glp－1激动剂和胃泌素化合物的联合使用 |
| DE102004043153B4 (de) * | 2004-09-03 | 2013-11-21 | Philipps-Universität Marburg | Erfindung betreffend GLP-1 und Exendin |
| MX2008002028A (es) * | 2005-08-11 | 2008-03-27 | Amylin Pharmaceuticals Inc | Polipeptidos hibridos con propiedades de seleccion. |
| CN1935846A (zh) * | 2005-09-14 | 2007-03-28 | 王庆华 | 一种用于治疗糖尿病的融合蛋白及其制备方法和应用 |
| SI2173890T1 (sl) | 2007-06-21 | 2011-06-30 | Univ Muenchen Tech | Biološko aktivni proteini, ki imajo povečano in vivo in/ali in vitro stabilnost |
| MX2010004298A (es) * | 2007-10-30 | 2010-05-03 | Univ Indiana Res & Tech Corp | Compuestos que exhiben actividad antagonista de glucagon y agonista de glp-1. |
| EP2443146B1 (en) | 2009-06-16 | 2016-10-05 | Indiana University Research And Technology Corporation | Gip receptor-active glucagon compounds |
| MX2012013001A (es) * | 2010-05-13 | 2013-02-26 | Univ Indiana Res & Tech Corp | Peptidos de la superfamilia de glucagon que presentan actividad del receptor nuclear de hormonas. |
| TWI617574B (zh) * | 2012-12-11 | 2018-03-11 | 梅迪繆思有限公司 | 用於治療肥胖之升糖素與ｇｌｐ－１共促效劑 |
-
2013
- 2013-12-05 TW TW102144692A patent/TWI617574B/zh active
- 2013-12-05 TW TW107102837A patent/TWI674270B/zh active
- 2013-12-10 LT LTEP13849992.6T patent/LT2931745T/lt unknown
- 2013-12-10 BR BR112015012238-8A patent/BR112015012238B1/pt active IP Right Grant
- 2013-12-10 EP EP18182274.3A patent/EP3495380B1/en active Active
- 2013-12-10 SM SM20180611T patent/SMT201800611T1/it unknown
- 2013-12-10 WO PCT/IB2013/003191 patent/WO2014091316A2/en not_active Ceased
- 2013-12-10 ES ES18182274T patent/ES2926713T3/es active Active
- 2013-12-10 DK DK18182274.3T patent/DK3495380T3/da active
- 2013-12-10 HU HUE13849992A patent/HUE039952T2/hu unknown
- 2013-12-10 KR KR1020157015139A patent/KR102080366B1/ko active Active
- 2013-12-10 CN CN201380062842.3A patent/CN104822699B/zh active Active
- 2013-12-10 PT PT13849992T patent/PT2931745T/pt unknown
- 2013-12-10 ES ES13849992T patent/ES2698329T3/es active Active
- 2013-12-10 SG SG10201801159WA patent/SG10201801159WA/en unknown
- 2013-12-10 MX MX2015006568A patent/MX365458B/es active IP Right Grant
- 2013-12-10 SI SI201331995T patent/SI3495380T1/sl unknown
- 2013-12-10 RS RS20220574A patent/RS63305B1/sr unknown
- 2013-12-10 SM SM20220266T patent/SMT202200266T1/it unknown
- 2013-12-10 US US14/650,469 patent/US9765130B2/en active Active
- 2013-12-10 HR HRP20220734TT patent/HRP20220734T1/hr unknown
- 2013-12-10 PL PL18182274.3T patent/PL3495380T3/pl unknown
- 2013-12-10 SI SI201331220T patent/SI2931745T1/sl unknown
- 2013-12-10 MX MX2019006260A patent/MX388904B/es unknown
- 2013-12-10 JP JP2015546105A patent/JP6490011B2/ja active Active
- 2013-12-10 RU RU2015127780A patent/RU2671088C2/ru active
- 2013-12-10 DK DK13849992.6T patent/DK2931745T3/en active
- 2013-12-10 AU AU2013356934A patent/AU2013356934C1/en not_active Ceased
- 2013-12-10 RU RU2018137842A patent/RU2018137842A/ru unknown
- 2013-12-10 PT PT181822743T patent/PT3495380T/pt unknown
- 2013-12-10 CA CA2893445A patent/CA2893445C/en active Active
- 2013-12-10 HR HRP20181678TT patent/HRP20181678T1/hr unknown
- 2013-12-10 PL PL13849992T patent/PL2931745T3/pl unknown
- 2013-12-10 AR ARP130104612A patent/AR093903A1/es unknown
- 2013-12-10 EP EP13849992.6A patent/EP2931745B1/en active Active
- 2013-12-10 CN CN201910117184.2A patent/CN109776670A/zh active Pending
- 2013-12-10 RS RS20181267A patent/RS57899B1/sr unknown
- 2013-12-10 TR TR2018/15172T patent/TR201815172T4/tr unknown
- 2013-12-10 SG SG11201503230XA patent/SG11201503230XA/en unknown
- 2013-12-10 LT LTEP18182274.3T patent/LT3495380T/lt unknown
-
2017
- 2017-08-10 US US15/673,826 patent/US10556939B2/en active Active
- 2017-11-15 AU AU2017261505A patent/AU2017261505C1/en not_active Ceased
-
2018
- 2018-11-21 CY CY181101228T patent/CY1121114T1/el unknown
-
2019
- 2019-11-29 AU AU2019272054A patent/AU2019272054A1/en not_active Abandoned
- 2019-12-20 US US16/723,645 patent/US11230584B2/en not_active Expired - Fee Related
-
2021
- 2021-12-14 US US17/550,269 patent/US20220098265A1/en not_active Abandoned
-
2022
- 2022-06-24 CY CY20221100439T patent/CY1125302T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20220734T1 (hr) | Koagonisti glukagona i glp-1 za liječenje pretilosti | |
| HRP20170086T1 (hr) | Bifunkcionalni polipeptidi | |
| JP2016512213A5 (https=) | ||
| NZ610075A (en) | Cxcr2 binding polypeptides | |
| WO2010013012A3 (en) | Hypothermia inducing polypeptides and uses thereof | |
| MX361076B (es) | Proteínas multifunción que comprenden complejo mayor de histocompatibilidad (cmh) de clase i multivalente unido mediante disulfuro. | |
| JP2015212284A5 (https=) | ||
| PL397167A1 (pl) | Przeciwnowotworowe bialko fuzyjne | |
| MX341925B (es) | Anticuerpos con funcion efectora suprimida o mejorada. | |
| WO2018057735A8 (en) | Antibodies for siglec-15 and methods of use thereof | |
| NZ599140A (en) | Antibodies that specifically bind to the epha2 receptor | |
| TN2012000518A1 (en) | Serum albumin binding molecules | |
| NZ602634A (en) | Vista regulatory t cell mediator protein, vista binding agents and use thereof | |
| BR112015020587A2 (pt) | proteínas de fusão de apelina e suas utilizações | |
| HRP20161608T1 (hr) | Modificirani tuberkulozni antigeni | |
| HK1200842A1 (en) | Proteins with improved half-life and other properties | |
| BR112012031329A2 (pt) | proteínas de fusão diméricas vstm3 e composições e métodos relacionados | |
| UY31123A1 (es) | Proteinas de fusion natriureticas | |
| JP2012509900A5 (https=) | ||
| WO2009020677A3 (en) | Compositions and methods for inhibiting g protein signaling | |
| JP2017501728A5 (https=) | ||
| WO2011063003A3 (en) | Peptides and methods for the detection of lyme disease antibodies | |
| EP2403871A4 (en) | FOR ABUSED PRION PROTEIN SPECIFIC ANTIBODIES AND EPITOPES | |
| HRP20150664T1 (hr) | Antikancerogeni fuzijski protein | |
| MX2021000030A (es) | Metodos y composiciones que utilizan polipeptidos variantes klotho. |